어떤 서비스가 필요하신가요? 문의 의뢰

NCT06634875

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

← 임상시험 허브

레지스트리 요약

진행 상태: 모집중 (RECRUITING)
질환/조건: Colorectal Cancer Metastatic
시험 유형: 중재 연구 (INTERVENTIONAL)
단계: Phase 2
목적: 치료
중재 유형: 약물
개입·치료: isunakinra
Lead Sponsor: Buzzard Pharmaceuticals (산업계)

캐시 시각: 2026-10-24 01:14:35

ClinicalTrials.gov에서 보기

요약

This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.

문의

이 시험 기반 리포트·메디컬라이팅이 필요하시면 문의해 주세요.

리포트 문의 메디컬라이팅 문의 맞춤 리서치 리포트

고객센터 문의